CRIP1

Summary

CRIP1 (cysteine rich protein 1, HGNC:2360) is a protein-coding gene on chromosome 14q32.33, encoding Cysteine-rich protein 1 (P50238). Seems to have a role in zinc absorption and may function as an intracellular zinc transport protein.

Cysteine-rich intestinal protein (CRIP) belongs to the LIM/double zinc finger protein family, members of which include cysteine- and glycine-rich protein-1 (CSRP1; MIM 123876), rhombotin-1 (RBTN1; MIM 186921), rhombotin-2 (RBTN2; MIM 180385), and rhombotin-3 (RBTN3; MIM 180386). CRIP may be involved in intestinal zinc transport (Hempe and Cousins, 1991 [PubMed 1946385]).

Source: NCBI Gene 1396 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 40 total
• MANE Select transcript: NM_001311

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2360
Approved symbol	CRIP1
Name	cysteine rich protein 1
Location	14q32.33
Locus type	gene with protein product
Status	Approved
Aliases	CRIP
Ensembl gene	ENSG00000213145
Ensembl biotype	protein_coding
OMIM	123875
Entrez	1396

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 9 protein_coding, 3 retained_intron

ENST00000330233, ENST00000392531, ENST00000409393, ENST00000460900, ENST00000461556, ENST00000496700, ENST00000903614, ENST00000903615, ENST00000903616, ENST00000919629, ENST00000919630, ENST00000945681

RefSeq mRNA: 1 — MANE Select: NM_001311 NM_001311

CCDS: CCDS10004

Canonical transcript exons

ENST00000392531 — 6 exons

Exon	Start	End
ENSE00001512301	105486886	105486972
ENSE00003574945	105488663	105488947
ENSE00003610506	105488331	105488388
ENSE00003620130	105488471	105488516
ENSE00003648579	105487199	105487299
ENSE00003672351	105488166	105488260

Expression profiles

Bgee: expression breadth ubiquitous, 132 present calls, max score 99.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 47.8423 / max 1870.7447, expressed in 1221 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
141938	42.5533	1202
141939	2.7052	419
141935	1.7234	254
141940	0.2445	152
141936	0.2150	104
141937	0.1455	72
141941	0.1042	38
141928	0.0539	18
141930	0.0452	12
141931	0.0337	17

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right coronary artery	UBERON:0001625	99.52	gold quality
granulocyte	CL:0000094	99.42	gold quality
left coronary artery	UBERON:0001626	99.09	gold quality
popliteal artery	UBERON:0002250	98.95	gold quality
tibial artery	UBERON:0007610	98.95	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	98.88	gold quality
right uterine tube	UBERON:0001302	98.84	gold quality
ascending aorta	UBERON:0001496	98.80	gold quality
thoracic aorta	UBERON:0001515	98.76	gold quality
descending thoracic aorta	UBERON:0002345	98.60	gold quality
leukocyte	CL:0000738	97.77	gold quality
duodenum	UBERON:0002114	97.74	gold quality
monocyte	CL:0000576	97.63	gold quality
apex of heart	UBERON:0002098	97.58	gold quality
right atrium auricular region	UBERON:0006631	97.37	gold quality
skin of abdomen	UBERON:0001416	97.34	gold quality
zone of skin	UBERON:0000014	97.23	gold quality
lymph node	UBERON:0000029	97.21	gold quality
upper lobe of left lung	UBERON:0008952	97.19	gold quality
skin of leg	UBERON:0001511	97.12	gold quality
colonic epithelium	UBERON:0000397	97.02	gold quality
fallopian tube	UBERON:0003889	96.99	gold quality
omental fat pad	UBERON:0010414	96.98	gold quality
small intestine	UBERON:0002108	96.97	gold quality
vermiform appendix	UBERON:0001154	96.79	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.74	gold quality
adipose tissue	UBERON:0001013	96.73	gold quality
subcutaneous adipose tissue	UBERON:0002190	96.54	gold quality
mucosa of transverse colon	UBERON:0004991	96.33	gold quality
blood	UBERON:0000178	96.20	gold quality

Single-cell (SCXA)

Detected in 42 experiment(s), a significant marker in 37.

Experiment	Marker?	Max mean expression
E-MTAB-6308	yes	13028.30
E-MTAB-6653	yes	8476.17
E-GEOD-130148	yes	7837.67
E-MTAB-8410	yes	6235.12
E-MTAB-8221	yes	6215.47
E-MTAB-8381	yes	6117.58
E-GEOD-124263	yes	4107.04
E-MTAB-10287	yes	3999.33
E-MTAB-10283	yes	3773.11
E-MTAB-6701	yes	3772.01
E-GEOD-124472	yes	2940.26
E-GEOD-134144	yes	2710.24
E-HCAD-8	yes	2489.10
E-MTAB-10885	yes	2300.60
E-MTAB-11011	yes	2180.35

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

10 targeting CRIP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-4688	99.48	64.68	828
HSA-MIR-6743-5P	99.48	63.60	721
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-299-5P	98.56	71.14	1140
HSA-MIR-3173-5P	97.35	65.82	1282
HSA-MIR-6799-3P	97.35	65.60	1302
HSA-MIR-6789-5P	94.05	66.19	285

Literature-anchored findings (GeneRIF, showing 14)

• CRIP1 expression is associated with long-term survival and no metastases in osteosarcoma patients. (PMID:22202598)
• This study provides evidence for a prognostic clinical potential of the combined study of GAL-3 and CRIP-1 in endometrial cancer (PMID:26708131)
• CRIP1 gene expression was correlated to measures of cardiac hypertrophy in Hypertension patients. Assessment of circulating CRIP1 (cystein-rich protein 1) levels as biomarkers showed a strong association with increased risk for incident stroke. (PMID:28784648)
• CRIP1 acts as an oncogene in the cell proliferation, migration, and invasion processes of thyroid carcinoma. CRIP1 may serve well as an independent prognostic marker with significant predictive power for use in thyroid carcinoma therapy. (PMID:29059670)
• The CRIP1 expression level was highest in the highly metastatic colon cancer cell lines and CRIP1 silencing did not significantly affect the percentage of apoptotic SW620 and HT29 cells. (PMID:29179181)
• CRIP1 promotes cell migration and invasion, mediates epithelial-mesenchymal transition, and activates the Wnt/betacatenin signaling pathway in cervical cancer (PMID:29959029)
• The current research reveals a vital role of CRIP1 in colorectal cancer(CRC) progression, which provide a novel target for clinical drug resistance of colorectal cancer and undoubtedly contributing to the therapeutic strategies in CRC. (PMID:30850009)
• CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy. (PMID:34262130)
• Cysteine-Rich Intestinal Protein 1 Served as an Epithelial Ovarian Cancer Marker via Promoting Wnt/beta-Catenin-Mediated EMT and Tumour Metastasis. (PMID:34413913)
• Comprehensive Analysis of CRIP1 in Patients with Ovarian Cancer, including ceRNA Network, Immune-Infiltration Pattern, and Clinical Benefit. (PMID:35140819)
• CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma. (PMID:35775648)
• CRIP1 supports the growth and migration of AML-M5 subtype cells by activating Wnt/beta-catenin pathway. (PMID:37224580)
• CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-kappaB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. (PMID:37541772)
• CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. (PMID:38199044)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Crip1	ENSMUSG00000006360
rattus_norvegicus	Crip1	ENSRNOG00000027990

Paralogs (20): FHL1 (ENSG00000022267), LMO3 (ENSG00000048540), LHX5 (ENSG00000089116), ZFHX4 (ENSG00000091656), LHX2 (ENSG00000106689), LHX6 (ENSG00000106852), LHX3 (ENSG00000107187), LHX4 (ENSG00000121454), LMO2 (ENSG00000135363), ZFHX2 (ENSG00000136367), LMX1B (ENSG00000136944), ZFHX3 (ENSG00000140836), LMO4 (ENSG00000143013), LHX9 (ENSG00000143355), CRIP3 (ENSG00000146215), LHX8 (ENSG00000162624), LMX1A (ENSG00000162761), LMO1 (ENSG00000166407), CRIP2 (ENSG00000182809), LHX1 (ENSG00000273706)

Protein

Protein identifiers

Cysteine-rich protein 1 — P50238 (reviewed: P50238)

Alternative names: Cysteine-rich heart protein, Cysteine-rich intestinal protein

All UniProt accessions (1): P50238

UniProt curated annotations — full annotation on UniProt →

Function. Seems to have a role in zinc absorption and may function as an intracellular zinc transport protein.

RefSeq proteins (1): NP_001302* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001781	Znf_LIM	Domain

Pfam: PF00412

UniProt features (6 total): modified residue 3, chain 1, domain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P50238-F1	82.41	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 9, 22, 68

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 373 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, BENPORATH_ES_WITH_H3K27ME3, GOBP_RESPONSE_TO_ZINC_ION, GOBP_GLAND_MORPHOGENESIS, GOBP_PROSTATE_GLAND_MORPHOGENESIS, GOBP_CELLULAR_RESPONSE_TO_UV, BASSO_B_LYMPHOCYTE_NETWORK, YANG_BREAST_CANCER_ESR1_BULK_UP, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, MODULE_45, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER, GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP, GOBP_RESPONSE_TO_METAL_ION, TRAYNOR_RETT_SYNDROM_DN

GO Biological Process (8): immune response (GO:0006955), heart development (GO:0007507), intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630), response to zinc ion (GO:0010043), regulation of gene expression (GO:0010468), prostate gland stromal morphogenesis (GO:0060741), cellular response to antibiotic (GO:0071236), cellular response to UV-B (GO:0071493)

GO Molecular Function (3): zinc ion binding (GO:0008270), peptide binding (GO:0042277), metal ion binding (GO:0046872)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune system process	1
response to stimulus	1
animal organ development	1
circulatory system development	1
DNA damage response	1
intrinsic apoptotic signaling pathway	1
response to metal ion	1
gene expression	1
regulation of macromolecule biosynthetic process	1
developmental process involved in reproduction	1
anatomical structure morphogenesis	1
prostate gland morphogenesis	1
connective tissue development	1
response to antibiotic	1
cellular response to chemical stimulus	1
response to UV-B	1
cellular response to UV	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

566 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CRIP1	LMO1	P25800	774
CRIP1	LMO2	P25791	614
CRIP1	SPARC	P09486	576
CRIP1	MTA1	Q13330	469
CRIP1	AGO2	Q9UKV8	468
CRIP1	FGD2	Q7Z6J4	468
CRIP1	ASB9	Q96DX5	448
CRIP1	S100A6	P06703	437
CRIP1	MMUT	P22033	432
CRIP1	CNR1	P21554	430
CRIP1	ANXA2	P07355	417
CRIP1	RPAIN	Q86UA6	405
CRIP1	ANXA1	P04083	403
CRIP1	GPD1L	Q8N335	399
CRIP1	S100A10	P08206	389

IntAct

12 interactions, top by confidence:

A	B	Type	Score
CRIP1	TK1	psi-mi:“MI:0914”(association)	0.530
	TK2	psi-mi:“MI:0915”(physical association)	0.400
SH2D3C	ANXA2P2	psi-mi:“MI:0914”(association)	0.350
PRKD1		psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
CRIP1	VOPP1	psi-mi:“MI:0915”(physical association)	0.000
CRIP1	HAP1	psi-mi:“MI:0915”(physical association)	0.000
CRIP1	SH3GL3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (58): ADSL (Co-fractionation), AK2 (Co-fractionation), ATOX1 (Co-fractionation), CFL1 (Co-fractionation), CFL2 (Co-fractionation), CKMT1B (Co-fractionation), CKMT1A (Co-fractionation), CRIP1 (Co-fractionation), CRIP1 (Co-fractionation), CRIP1 (Co-fractionation), CRIP1 (Co-fractionation), CRIP1 (Co-fractionation), CRIP1 (Co-fractionation), CRIP1 (Co-fractionation), CRIP1 (Co-fractionation)

ESM2 similar proteins: O00151, O04193, O35115, O70400, O70433, O80839, P21291, P29675, P36201, P47875, P50238, P50461, P50462, P50463, P50464, P52943, P52944, P53777, P63254, P63255, P67966, P67967, P97315, Q0VFX8, Q14192, Q16527, Q1ECF5, Q1LZA7, Q24400, Q2KI95, Q3MHY1, Q4KM31, Q4U0T9, Q500W4, Q56K04, Q5E9E1, Q5R7Y1, Q5RCT4, Q5RGJ5, Q5ZLR4

Diamond homologs: A8DZE6, E1BKA3, F1MF74, F1QH17, F1QWK4, G3MWR8, O04193, O14014, O80839, P21291, P29675, P34416, P36201, P47875, P50238, P50460, P50461, P50462, P50463, P52943, P53410, P53777, P63254, P63255, P67966, P67967, P97314, P97315, Q04584, Q05158, Q0VFX8, Q13642, Q14192, Q16527, Q1ECF5, Q24400, Q2KI95, Q32LE9, Q3MHY1, Q4U0T9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

40 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	0
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

741 predictions. Top by Δscore:

Variant	Effect	Δscore
14:105486508:G:GT	donor_gain	1.0000
14:105488164:A:AG	acceptor_gain	1.0000
14:105488165:G:GA	acceptor_gain	1.0000
14:105488327:GCA:G	acceptor_loss	1.0000
14:105488329:A:AG	acceptor_gain	1.0000
14:105488329:A:C	acceptor_loss	1.0000
14:105488330:G:GA	acceptor_gain	1.0000
14:105488330:GC:G	acceptor_gain	1.0000
14:105488330:GCAC:G	acceptor_gain	1.0000
14:105488384:TAAAG:T	donor_loss	1.0000
14:105488385:AAAGG:A	donor_loss	1.0000
14:105488386:AAGG:A	donor_loss	1.0000
14:105488388:GGTAT:G	donor_loss	1.0000
14:105488389:G:T	donor_loss	1.0000
14:105488390:T:A	donor_loss	1.0000
14:105488469:A:AG	acceptor_gain	1.0000
14:105488469:AGGC:A	acceptor_loss	1.0000
14:105488470:G:A	acceptor_loss	1.0000
14:105488470:G:GA	acceptor_gain	1.0000
14:105488514:CAGG:C	donor_loss	1.0000
14:105488516:GGTA:G	donor_loss	1.0000
14:105488517:G:GA	donor_loss	1.0000
14:105488518:T:G	donor_loss	1.0000
14:105486370:A:G	donor_gain	0.9900
14:105486482:TCCTC:T	donor_gain	0.9900
14:105486575:G:GT	donor_gain	0.9900
14:105486584:G:T	donor_gain	0.9900
14:105488161:T:TA	acceptor_gain	0.9900
14:105488161:TGCA:T	acceptor_loss	0.9900
14:105488164:A:T	acceptor_loss	0.9900

AlphaMissense

504 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:105487269:T:C	C4R	0.998
14:105488195:T:A	W24R	0.998
14:105488195:T:C	W24R	0.998
14:105488197:G:C	W24C	0.998
14:105488197:G:T	W24C	0.998
14:105488207:T:C	C28R	0.998
14:105488349:T:A	C52S	0.998
14:105488350:G:C	C52S	0.998
14:105488207:T:A	C28S	0.997
14:105488208:G:C	C28S	0.997
14:105488216:T:C	C31R	0.997
14:105488349:T:C	C52R	0.997
14:105488350:G:A	C52Y	0.997
14:105488361:T:C	C56R	0.997
14:105488376:T:C	F61L	0.997
14:105488378:T:A	F61L	0.997
14:105488378:T:G	F61L	0.997
14:105487271:T:G	C4W	0.996
14:105488198:C:A	H25N	0.996
14:105488200:T:A	H25Q	0.996
14:105488200:T:G	H25Q	0.996
14:105488209:C:G	C28W	0.996
14:105488211:T:C	L29P	0.996
14:105488216:T:A	C31S	0.996
14:105488217:G:C	C31S	0.996
14:105488361:T:A	C56S	0.996
14:105488362:G:C	C56S	0.996
14:105487278:T:C	C7R	0.995
14:105488198:C:G	H25D	0.995
14:105488208:G:A	C28Y	0.995

dbSNP variants (sampled 300 via entrez): RS1000295542 (14:105488052 C>A,G,T), RS1000667177 (14:105487883 C>T), RS1001031537 (14:105487090 C>A,T), RS1001472181 (14:105487815 G>A), RS1001839283 (14:105487601 C>G), RS1003110800 (14:105486418 G>C), RS1003475743 (14:105485492 C>A,G,T), RS1003548203 (14:105486642 G>A,C,T), RS1003852628 (14:105485267 C>T), RS1004541725 (14:105487549 C>G,T), RS1004762604 (14:105487376 G>A,T), RS1006219165 (14:105486397 G>A,C), RS1006436563 (14:105486171 C>G), RS1008036610 (14:105485576 A>G), RS1008100122 (14:105489328 T>C,G)

Disease associations

OMIM: gene MIM:123875 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, increases methylation, affects cotreatment	8
Estradiol	affects expression, affects cotreatment, increases expression, decreases expression	4
bisphenol A	affects expression, decreases expression, increases expression	3
trichostatin A	affects cotreatment, increases expression	3
entinostat	increases expression, affects cotreatment	2
belinostat	affects cotreatment, increases expression	2
Resveratrol	decreases expression, increases expression	2
Air Pollutants	increases abundance, increases expression	2
Cisplatin	affects cotreatment, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
aristolochic acid I	increases expression	1
bisphenol F	increases expression	1
methylmercuric chloride	decreases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
sodium arsenate	decreases expression, increases abundance	1
arsenite	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
paricalcitol	affects cotreatment, increases expression	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
trans-10,cis-12-conjugated linoleic acid	increases expression	1
abrine	decreases expression	1
dorsomorphin	increases expression, affects cotreatment	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery